Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

General Research Article

Salinomycin Suppresses Tumorigenicity of Liver Cancer Stem Cells and Wnt/Beta-catenin Signaling

Author(s): Qiuping Liu , Jinghui Sun, Qing Luo, Yang Ju and Guanbin Song*

Volume 16, Issue 5, 2021

Published on: 23 January, 2020

Page: [630 - 637] Pages: 8

DOI: 10.2174/1574888X15666200123121225

Price: $65

Abstract

Background: Accumulating evidence has revealed the important role of Cancer Stem Cells (CSCs) in driving tumor initiation and tumor relapse or metastasis. Therapeutic strategies that selectively target CSCs may be effective approaches to eliminate cancer. Salinomycin, an antitumor agent, was identified as a selective inhibitor of several types of CSCs. We previously reported that salinomycin inhibits the migration and invasiveness of Liver Cancer Stem Cells (LCSCs).

Objective: This study was conducted to explore the role of salinomycin in suppressing the stemness properties of LCSCs and the mechanism.

Methods: LCSCs were identified and enriched from MHCC97H cells. Salinomycin was used to treat LCSCs at the indicated concentrations. Sphere formation ability, chemotherapy resistance, expression of CSC surface markers, Young’s modulus and tumorigenicity of LCSCs were assessed to evaluate the effect of salionmycin on LCSCs. The expression of β-catenin was evaluated by western blotting. LiCl was used to activate the Wnt/β-catenin signaling pathway.

Results: Salinomycin suppresses the stemness properties of LCSCs. Moreover, salinomycin could also inhibit the activation of Wnt/β-catenin signaling in LCSCs. Nevertheless, the stemness properties of LCSCs could be recovered when Wnt/β-catenin signaling was activated by LiCl. Further studies demonstrated that salinomycin also significantly reduces the tumorigenicity of LCSCs in vivo by suppressing the Wnt/β-catenin signaling pathway.

Conclusion: Salinomycin could suppress stemness properties and induce differentiation of LCSCs through the Wnt/β-catenin signaling pathway, which provides evidence that salinomycin may serve as a potential drug for liver cancer therapy targeting LCSCs in the clinic.

Keywords: Liver cancer stem cells, salinomycin, stemness, differentiation, Wnt/β-catenin signaling pathway, liver cancer therapy.

« Previous
[1]
Nio K, Yamashita T, Kaneko S. The evolving concept of liver cancer stem cells. Mol Cancer 2017; 16(1): 4.
[http://dx.doi.org/10.1186/s12943-016-0572-9] [PMID: 28137313]
[2]
Vlashi E, Pajonk F. Cancer stem cells, cancer cell plasticity and radiation therapy. Semin Cancer Biol 2015; 31: 28-35.
[http://dx.doi.org/10.1016/j.semcancer.2014.07.001] [PMID: 25025713]
[3]
Yang ZF, Ngai P, Ho DW, et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008; 47(3): 919-28.
[http://dx.doi.org/10.1002/hep.22082] [PMID: 18275073]
[4]
Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5(4): 275-84.
[http://dx.doi.org/10.1038/nrc1590] [PMID: 15803154]
[5]
Kurtova AV, Xiao J, Mo Q, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 2015; 517(7533): 209-13.
[http://dx.doi.org/10.1038/nature14034] [PMID: 25470039]
[6]
Li Y, Rogoff HA, Keates S, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci USA 2015; 112(6): 1839-44.
[http://dx.doi.org/10.1073/pnas.1424171112] [PMID: 25605917]
[7]
Miyazaki Y, Shibuya M, Sugawara H, Kawaguchi O, Hirsoe C. Salinomycin, a new polyether antibiotic. J Antibiot 1974; 27(11): 814-21.
[http://dx.doi.org/10.7164/antibiotics.27.814] [PMID: 4452657]
[8]
Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138(4): 645-59.
[http://dx.doi.org/10.1016/j.cell.2009.06.034] [PMID: 19682730]
[9]
Naujokat C, Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol 2012; 2012: 950658.
[http://dx.doi.org/10.1155/2012/950658] [PMID: 23251084]
[10]
An H, Kim JY, Oh E, Lee N, Cho Y, Seo JH. Salinomycin promotes anoikis and decreases the CD44+/CD24- stem-like population via inhibition of STAT3 activation in MDA-MB-231 cells. PLoS One 2015; 10(11): e0141919.
[http://dx.doi.org/10.1371/journal.pone.0141919] [PMID: 26528725]
[11]
Sun J, Luo Q, Liu L, Yang X, Zhu S, Song G. Salinomycin attenuates liver cancer stem cell motility by enhancing cell stiffness and increasing F-actin formation via the FAK-ERK1/2 signalling pathway. Toxicology 2017; 384: 1-10.
[http://dx.doi.org/10.1016/j.tox.2017.04.006] [PMID: 28395993]
[12]
Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 2012; 149(6): 1192-205.
[http://dx.doi.org/10.1016/j.cell.2012.05.012] [PMID: 22682243]
[13]
Nusse R. Wnt signaling and stem cell control. Cell Res 2008; 18(5): 523-7.
[http://dx.doi.org/10.1038/cr.2008.47] [PMID: 18392048]
[14]
Malanchi I, Peinado H, Kassen D, et al. Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling. Nature 2008; 452(7187): 650-3.
[http://dx.doi.org/10.1038/nature06835] [PMID: 18385740]
[15]
Jang GB, Kim JY, Cho SD, et al. Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. Sci Rep 2015; 5: 12465-79.
[http://dx.doi.org/10.1038/srep12465] [PMID: 26202299]
[16]
Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 2009; 19(6): 683-97.
[http://dx.doi.org/10.1038/cr.2009.43] [PMID: 19365403]
[17]
Miclea RL, van der Horst G, Robanus-Maandag EC, et al. Apc bridges Wnt/β-catenin and BMP signaling during osteoblast differentiation of KS483 cells. Exp Cell Res 2011; 317(10): 1411-21.
[http://dx.doi.org/10.1016/j.yexcr.2011.03.007] [PMID: 21402068]
[18]
Sun J, Luo Q, Liu L, et al. Biomechanical profile of cancer stem-like cells derived from MHCC97H cell lines. J Biomech 2016; 49(1): 45-52.
[http://dx.doi.org/10.1016/j.jbiomech.2015.11.007] [PMID: 26627368]
[19]
Sun J, Luo Q, Liu L, Song G. Low-level shear stress induces differentiation of liver cancer stem cells via the Wnt/β-catenin signalling pathway. Exp Cell Res 2019; 375(1): 90-6.
[http://dx.doi.org/10.1016/j.yexcr.2018.12.023] [PMID: 30599139]
[20]
Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008; 456(7222): 593-8.
[http://dx.doi.org/10.1038/nature07567] [PMID: 19052619]
[21]
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100(7): 3983-8.
[http://dx.doi.org/10.1073/pnas.0530291100] [PMID: 12629218]
[22]
de Sousa E, Melo F, Vermeulen L, Vermeulen L. Wnt signaling in cancer stem cell biology. Cancers 2016; 8(7): 60-77.
[http://dx.doi.org/10.3390/cancers8070060] [PMID: 27355964]
[23]
Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010; 16(12): 3153-62.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-2943] [PMID: 20530697]
[24]
Sun JH, Luo Q, Liu LL, Song GB. Liver cancer stem cell markers: Progression and therapeutic implications. World J Gastroenterol 2016; 22(13): 3547-57.
[http://dx.doi.org/10.3748/wjg.v22.i13.3547] [PMID: 27053846]
[25]
Zhu Z, Hao X, Yan M, et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 2010; 126(9): 2067-78.
[PMID: 19711346]
[26]
Suresh S. Biomechanics and biophysics of cancer cells. Acta Biomater 2007; 3(4): 413-38.
[http://dx.doi.org/10.1016/j.actbio.2007.04.002] [PMID: 17540628]
[27]
Crick SL, Yin FC. Assessing micromechanical properties of cells with atomic force microscopy: importance of the contact point. Biomech Model Mechanobiol 2007; 6(3): 199-210.
[http://dx.doi.org/10.1007/s10237-006-0046-x] [PMID: 16775736]
[28]
Guck J, Schinkinger S, Lincoln B, et al. Optical deformability as an inherent cell marker for testing malignant transformation and metastatic competence. Biophys J 2005; 88(5): 3689-98.
[http://dx.doi.org/10.1529/biophysj.104.045476] [PMID: 15722433]
[29]
Li QS, Lee GYH, Ong CN, Lim CT. AFM indentation study of breast cancer cells. Biochem Biophys Res Commun 2008; 374(4): 609-13.
[http://dx.doi.org/10.1016/j.bbrc.2008.07.078] [PMID: 18656442]
[30]
Ketene AN, Schmelz EM, Roberts PC, Agah M. The effects of cancer progression on the viscoelasticity of ovarian cell cytoskeleton structures. Nanomedicine 2012; 8(1): 93-102.
[http://dx.doi.org/10.1016/j.nano.2011.05.012] [PMID: 21704191]
[31]
Fuhrmann A, Staunton JR, Nandakumar V, Banyai N, Davies PCW, Ros R. AFM stiffness nanotomography of normal, metaplastic and dysplastic human esophageal cells. Phys Biol 2011; 8(1): 015007.
[http://dx.doi.org/10.1088/1478-3975/8/1/015007] [PMID: 21301067]
[32]
Takebe N, Harris PJ, Warren RQS, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011; 8(2): 97-106.
[http://dx.doi.org/10.1038/nrclinonc.2010.196] [PMID: 21151206]
[33]
Yin T, Wei H, Gou S, et al. Cancer stem-like cells enriched in Panc-1 spheres possess increased migration ability and resistance to gemcitabine. Int J Mol Sci 2011; 12(3): 1595-604.
[http://dx.doi.org/10.3390/ijms12031595] [PMID: 21673909]
[34]
Simeone DM. Pancreatic cancer stem cells: Implications for the treatment of pancreatic cancer. Clin Cancer Res 2008; 14(18): 5646-8.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-0584] [PMID: 18794070]
[35]
Lathia JD, Liu H. Overview of cancer stem cells and stemness for community oncologists. Target Oncol 2017; 12(4): 387-99.
[http://dx.doi.org/10.1007/s11523-017-0508-3] [PMID: 28664387]
[36]
Bardsley MR, Horváth VJ, Asuzu DT, et al. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 2010; 139(3): 942-52.
[http://dx.doi.org/10.1053/j.gastro.2010.05.083] [PMID: 20621681]
[37]
Kuo SZ, Blair KJ, Rahimy E, et al. Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt. BMC Cancer 2012; 12: 556.
[http://dx.doi.org/10.1186/1471-2407-12-556] [PMID: 23176396]
[38]
Yao H, Ashihara E, Maekawa T. Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin Ther Targets 2011; 15(7): 873-87.
[http://dx.doi.org/10.1517/14728222.2011.577418] [PMID: 21486121]
[39]
Yeung J, Esposito MT, Gandillet A, et al. β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010; 18(6): 606-18.
[http://dx.doi.org/10.1016/j.ccr.2010.10.032] [PMID: 21156284]
[40]
Zhang X, Lou Y, Wang H, et al. Wnt signaling regulates the stemness of lung cancer stem cells and its inhibitors exert anticancer effect on lung cancer SPC-A1 cells. Med Oncol 2015; 32(4): 95.
[http://dx.doi.org/10.1007/s12032-014-0462-1] [PMID: 25731617]
[41]
Yong X, Tang B, Xiao Y-F, et al. Helicobacter pylori upregulates Nanog and Oct4 via Wnt/β-catenin signaling pathway to promote cancer stem cell-like properties in human gastric cancer. Cancer Lett 2016; 374(2): 292-303.
[http://dx.doi.org/10.1016/j.canlet.2016.02.032] [PMID: 26940070]
[42]
Li X, Meng Y, Xie C, et al. Diallyl Trisulfide inhibits breast cancer stem cells via suppression of Wnt/β-catenin pathway. J Cell Biochem 2018; 119(5): 4134-41.
[http://dx.doi.org/10.1002/jcb.26613] [PMID: 29243835]
[43]
Preziosi M, Okabe H, Poddar M, Singh S, Monga SP. Endothelial Wnts regulate β-catenin signaling in murine liver zonation and regeneration: A sequel to the Wnt-Wnt situation. Hepatol Commun 2018; 2(7): 845-60.
[http://dx.doi.org/10.1002/hep4.1196] [PMID: 30027142]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy